Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

HEPARINISED SALINE INJECTION 10 IU/ML [SIN12253P]

Active ingredients: HEPARIN SODIUM (BOVINE MUCOSA) | SODIUM CHLORIDE

View product's general information
Last updated on 9 October 2026

Product Info

HEPARINISED SALINE INJECTION 10 IU/ML

[SIN12253P]

Product information

Active Ingredient and Strength

HEPARIN SODIUM (BOVINE MUCOSA) - 10 INTERNATIONAL UNITS/ML
SODIUM CHLORIDE - 0.9%

Dosage Form

INJECTION

Manufacturer and Country

B BRAUN MEDICAL INDUSTRIES SDN BHD - MALAYSIA

Registration Number

SIN12253P

Licence Holder

B. BRAUN SINGAPORE PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

B01AB51

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

Indications
Heparinised Saline Injection is used for flushing of in-dwelling cannulae and maintaining the patency of intravenous injection devices.

Dosing

Dosage and administration
To be determined by the attending physician. For flushing of in-dwelling cannulae, the usual recommended dose is 10 international units to 50 international units every 4 hours.

Contraindications

Contraindications
Heparin is contraindicated in patients who are hypersensitive to the drug. It is contraindicated in patients with haemorrhagic diseases; thrombocytopenia and patients who are haemorrhaging or are at risk of haemorrhage including those with haemophilia, subacute bacterial endocarditis, gastric or duodenal ulcer or severe hypertension. It is also contraindicated in patients who have recently undergone surgery at sites where haemorrhage would be an especial risk.